Introduction
============

Liver cancer (LC) rates are the lowest in the South-Central areas of Asia and Northern, Central, and Eastern regions of Europe and the highest in East and South-East Asia and Northern and Western Africa.[@b1-ott-11-2083] China alone accounts for about 50% of the total number of LC patients and LC-related deaths.[@b1-ott-11-2083],[@b2-ott-11-2083] Also, most of the LC patients have hepatocellular carcinoma (HCC). Although chronic hepatitis B virus (HBV) infection contributes to the major etiology of HCC,[@b3-ott-11-2083] other risk factors may also influence the development of HCC. Nowadays, obesity and overweight are becoming a prevalent problem, which may increase the susceptibility to various cancers.[@b4-ott-11-2083] Fatty liver is found commonly in patients with chronic HBV infection and might potentiate the risk of HBV-associated HCC by 7.3-fold.[@b5-ott-11-2083] It is thought that metabolism-related gene may influence the risk of HCC.

The excess of macronutrients stored results in overweight and obesity. Adipocytes may release many inflammatory mediators and lead to oxidative stress and proinflammatory states.[@b6-ott-11-2083] Inflammatory and oxidative stress are related to the development of malignancy.[@b7-ott-11-2083],[@b8-ott-11-2083] Leptin (LEP) and LEP receptor (LEPR) may be implicated in various signal pathways, such as JAK/STAT, MAPK, PI3K, and mTOR.[@b9-ott-11-2083] Also, these signal pathways were suggested to be correlated with carcinogenesis.[@b10-ott-11-2083],[@b11-ott-11-2083] Soga et al reported that fatty liver Shionogi-Lep/Lep mice developed hepatocellular adenomas and carcinomas following steatohepatitis.[@b12-ott-11-2083] In addition, high levels of LEP were found in sera of patients with HCC.[@b13-ott-11-2083] Thus, *LEP* and *LEPR* genes may impact on signal pathways and play an important role in the development of HCC.

Recently, some important *LEP* and *LEPR* single-nucleotide polymorphisms (SNPs) were explored for the susceptibility to a number of cancers. *LEP* rs7799039 A\>G, a promoter SNP, was suggested this variant was particularly affecting transcriptional level and LEP expression.[@b14-ott-11-2083] However, *LEP* rs2167270 G\>A is located in 5′-untranslated region and correlated with the translation process of *LEP* mRNA. Some previous meta-analyses suggested that *LEP* rs7799039 A\>G and rs2167270 G\>A variants conferred risk to cancer.[@b15-ott-11-2083]--[@b17-ott-11-2083] However, the association of *LEP* rs7799039 A\>G and rs2167270 G\>A polymorphisms with HCC risk is unknown.

*LEPR* rs1137100 G\>A and rs1137101 G\>A polymorphisms are two missense SNPs. Li et al reported that rs1137100 G\>A and rs1137101 G\>A polymorphisms in *LEPR* gene were correlated with susceptibility to HCC.[@b18-ott-11-2083] In individuals with chronic HBV infection, these two *LEPR* SNPs may be a biomarker for the susceptibility to HCC.[@b18-ott-11-2083] *LEPR* rs6588147 G\>A is an intron SNP. Slattery et al found this SNP caused colon cancer susceptibility among men.[@b19-ott-11-2083]

In view of these previous studies, we found that the relationship of *LEP* and *LEPR* polymorphisms with the development of cancer was unclear, especially in Asians.[@b20-ott-11-2083] In this study, we selected the *LEP* rs2167270 G\>A, rs7799039 A\>G, *LEPR* rs6588147 G\>A, rs1137100 G\>A, and rs1137101 G\>A SNPs and conducted a case--control study to determine the relationship between *LEP* and *LEPR* polymorphisms and HCC risk in Eastern Chinese Han population.

Patients and methods
====================

Subjects
--------

This case--control study was performed on two groups. The patient group consisted of 584 HCC cases (mean age 53.17±11.76 years) who were selected from the Department of Hepatobiliary Surgery at Fuzong Clinical Medical College (Fuzhou city, China) and Union Clinical Medical College (Fuzhou city, China) of Fujian Medical University through 2002--2016. HCC diagnosis was confirmed by pathology. Two hepatobiliary surgeons independently evaluated the disease stage according to the criteria of Barcelona Clinic Liver Cancer (2010). The control group consisted of 923 cancer-free participants (mean age 53.72±9.97 years). Written informed consent was signed by each participant included in this study. Approval from the Ethics Committee of Fujian Medical University was obtained. Each participant donated a blood sample which was stored in an EDTA vacutainer tube.

DNA extraction and genotyping
-----------------------------

The blood sample obtained from each participant was stored at −80°C immediately. Promega Genomic DNA Kit (Promega Corporation, Fitchburg, WI, USA) was used to extract and purify genomic DNA from lymphocytes. Purity and concentration of genomic DNA were determined by the NanoDrop ND-1000 spectrophotometer and 1.5% agarose gel electrophoresis. SNPscan™ genotyping method (Genesky Biotechologies Inc., Shanghai, China) was used to determine *LEP* rs2167270 G\>A, rs7799039 A\>G, *LEPR* rs6588147 G\>A, rs1137100 G\>A, and rs1137101 G\>A genotypes. Sixty sample sizes (4%) were randomly selected for quality control. The genotyping was performed by our technicians and the results were not changed.

Statistical analysis
--------------------

Data were analyzed by using SAS 9.4 software (SAS Institute, Cary, NC, USA). Continuous variables were expressed as mean±SD. Student's *t*-test was used to assess the differences in age distribution. Chi-square (*χ*^2^) or Fisher's exact test was used to assess the distribution of age, sex, chronic HBV infection status, smoking status, alcohol use, and genotypes. The deviation from Hardy--Weinberg equilibrium in the control group was determined by using an online calculator (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>)[@b21-ott-11-2083]--[@b25-ott-11-2083] to compare the observed genotype frequencies of *LEP* rs2167270 G\>A, rs7799039 A\>G, *LEPR* rs6588147 G\>A, rs1137100 G\>A, and rs1137101 G\>A SNPs with the expected frequencies. Using additive, homozygote, dominant, and recessive models, the associations between *LEP* rs2167270 G\>A, rs7799039 A\>G, *LEPR* rs6588147 G\>A, rs1137100 G\>A, and rs1137101 G\>A SNPs and susceptibility of HCC were assessed by crude/adjusted odds ratios (ORs) and confidence intervals (CIs). A *P*\<0.05 (two-tailed) was considered as the threshold for statistical significance. In this study, a Bonferroni correction method was used for multiple testing.[@b26-ott-11-2083],[@b27-ott-11-2083]

Results
=======

Baseline characteristics
------------------------

There were 584 HCC cases and 923 cancer-free controls included in our study. The frequency distributions for age, sex, chronic HBV infection status, smoking, and alcohol use among HCC patients and controls are summarized in [Table 1](#t1-ott-11-2083){ref-type="table"}. The characteristics of HCC cases and controls were fully matched by age and sex. The locus information of *LEP* rs2167270 G\>A, rs7799039 A\>G, *LEPR* rs6588147 G\>A, rs1137100 G\>A, and rs1137101 G\>A polymorphisms is shown in [Table 2](#t2-ott-11-2083){ref-type="table"}. The genotyping success rate for all SNPs was eligible (\>99%). Minor allele frequency of these SNPs was similar to the data of Chinese population. For these included SNPs, the genotype distribution in controls conformed to Hardy--Weinberg equilibrium.

Association of *LEP* rs2167270 G\>A, rs7799039 A\>G, *LEPR* rs6588147 G\>A, rs1137100 G\>A, and rs1137101 G\>A polymorphisms with the risk of HCC
-------------------------------------------------------------------------------------------------------------------------------------------------

[Table 3](#t3-ott-11-2083){ref-type="table"} lists the genotype distribution of *LEP* rs2167270 G\>A, rs7799039 A\>G, *LEPR* rs6588147 G\>A, rs1137100 G\>A, and rs1137101 G\>A polymorphisms.

Frequencies of *LEP* rs7799039 AA, AG, and GG genotypes were 51.30%, 38.43%, and 10.26% in HCC cases and 54.83%, 39.09%, and 6.08% in controls, respectively. When compared with the frequency of *LEP* rs7799039 AA genotype, a significant difference was found in the frequency of *LEP* rs7799039 GG genotype between HCC cases and controls (crude OR=1.76, 95% CI, 1.19--2.60, *P*=0.005). When compared with frequency of *LEP* rs7799039 AA/AG genotype, there was a difference in the frequency of *LEP* rs7799039 GG genotype between HCC patients and controls (crude OR=1.77, 95% CI, 1.21--2.59, *P*=0.004). Adjustments for age, sex, chronic HBV infection status, smoking, and drinking, this association was not essentially changed (GG vs AA: adjusted OR=2.03, 95% CI, 1.22--3.38, *P*=0.006 and GG vs AA/AG: adjusted OR=1.97, 95% CI, 1.20--3.22, *P*=0.007; [Table 3](#t3-ott-11-2083){ref-type="table"}).

Frequencies of *LEP* rs2167270 GG, GA, and AA genotypes were 59.65%, 34.43%, and 5.91% in HCC patients and 61.24%, 34.85%, and 3.91% in controls, respectively. The association between *LEP* rs2167270 G\>A polymorphism and a tendency for increased HCC risk was noted (AA vs GG: crude OR=1.52, 95% CI, 0.93--2.47, *P*=0.093 and AA vs GG/GA: crude OR=1.55, 95% CI, 0.96--2.50, *P*=0.076). Adjustments for age, sex, chronic HBV infection status, smoking, and drinking, this association was more significant (AA vs GG: adjusted OR=2.03, 95% CI, 1.10--3.75, *P*=0.024 and AA vs GG/GA: adjusted OR=2.01, 95% CI, 1.10--3.68, *P*=0.023; [Table 3](#t3-ott-11-2083){ref-type="table"}).

Frequencies of *LEPR* rs6588147 GG, GA, and AA genotypes were 77.22%, 21.39%, and 1.39% in HCC patients and 71.77%, 26.71%, and 1.52% in controls, respectively. When compared with the frequency of *LEPR* rs6588147 GG genotype, a significant difference was found in the frequency of *LEPR* rs6588147 GA genotype between HCC cases and controls (crude OR=0.73, 95% CI, 0.57--0.94, *P*=0.013). When compared with the frequency of *LEPR* rs6588147 GG genotype, there was a difference in the frequency of *LEPR* rs6588147 GA/AA genotype between HCC patients and controls (crude OR=0.75, 95% CI, 0.59--0.96, *P*=0.020). Adjustments for age, sex, chronic HBV infection status, smoking, and drinking, this association was more significant (GA vs GG: adjusted OR=0.62, 95% CI, 0.45--0.86, *P*=0.005 and AA/GA vs GG: adjusted OR=0.64; 95% CI, 0.47--0.88, *P*=0.007; [Table 3](#t3-ott-11-2083){ref-type="table"}).

However, we found no association between *LEPR* rs1137100 G\>A and rs1137101 G\>A polymorphisms and the risk of HCC in any genetic model ([Table 3](#t3-ott-11-2083){ref-type="table"}).

We used Bonferroni correction method to conduct a multiple testing. We found the genotype distribution of *LEP* rs7799039 A\>G and *LEPR* rs6588147 G\>A SNPs was still significantly different between HCC patients and cancer-free controls (*P*=0.006 and 0.007 for *LEP* rs7799039 A\>G, and *P*=0.005 and 0.007 for *LEPR* rs6588147 G\>A, respectively).

Discussion
==========

Although chronic HBV infection status is associated with the etiology of HCC, the individual's hereditary factor may influence the susceptibility to HCC. Recently, it is believed that the metabolic disturbance increases the susceptibility to many malignancies.[@b4-ott-11-2083] Thus, the metabolism-related gene may affect the development of HCC. In this case--control study, we explored the relationship of *LEP* rs2167270 G\>A, rs7799039 A\>G, *LEPR* rs6588147 G\>A, rs1137100 G\>A, and rs1137101 G\>A polymorphisms with the risk of HCC in 584 patients and 923 control subjects in Eastern Chinese Han population. We found that *LEP* rs7799039 A\>G and rs2167270 G\>A polymorphisms were associated with the susceptibility of HCC in this population. However, *LEPR* rs6588147 G\>A polymorphism decreased the risk of HCC. To our knowledge, this is the study with the largest sample size on the relationship between *LEP* rs2167270 G\>A, rs7799039 A\>G, *LEPR* rs6588147 G\>A, rs1137100 G\>A, and rs1137101 G\>A polymorphisms and HCC risk.

*LEP* rs7799039 A\>G is a promoter SNP, which was suggested it could affect transcriptional level and LEP expression.[@b14-ott-11-2083] In this study, we found that *LEP* rs7799039 A\>G polymorphism was associated with the susceptibility to HCC in Chinese Han population. Recently, a meta-analysis which included 16 published studies of 6,569 cancer cases and 8,405 controls demonstrated that *LEP* rs7799039 A\>G polymorphism may decrease the risk of cancer.[@b20-ott-11-2083] In addition, this association between *LEP* rs7799039 A\>G polymorphism and cancer risk was also found in other meta-analyses.[@b16-ott-11-2083],[@b17-ott-11-2083] However, the association between *LEP* rs7799039 A\>G polymorphism and the risk of cancer was seldom studied in Asian populations. Clearly, these ambiguous findings suggested that the functions of *LEP* rs7799039 A\>G variants might be different in different races. It was found that the minor allele frequency of *LEP* rs7799039 A\>G polymorphism might alter sharply among different populations (0.201 \[Chinese\] vs 0.597 \[Caucasians\]).[@b28-ott-11-2083] Recently, Romanowski et al reported that *LEP* rs2167270 G\>A polymorphism increased the risk of posttransplant diabetes mellitus.[@b29-ott-11-2083] *LEP* rs2167270 G\>A is located in 5′-untranslated region and may influence the translation process of *LEP* mRNA. A functional study demonstrated that serum LEP concentrations in *LEP* rs2167270 GA genotype were higher than in individuals with rs2167270 GG genotype.[@b30-ott-11-2083] In this study, the association between *LEP* rs2167270 G\>A polymorphism and increased risk of HCC was found, which was very similar to the findings of the previous meta-analysis.[@b15-ott-11-2083] In the future, more case--control studies should be carried out to explore the potential association of *LEP* rs7799039 A\>G and *LEP* rs2167270 G\>A polymorphisms with cancer risk in Asians.

Slattery et al reported that *LEPR* rs6588147 AA genotype had a tendency to lower susceptibility of colon cancer in a mixed population.[@b19-ott-11-2083] We found that rs6588147 A allele may be associated with the decreased susceptibility of HCC, which was similar to previous findings. In our study, after Bonferroni correction test, this association was still significant between HCC patients and cancer-free controls. However, Nyante et al identified that the *LEPR* rs6588147 G\>A polymorphism might confer susceptibility to breast cancer in luminal A subtype.[@b31-ott-11-2083] Only a few investigations focused on the correlation between *LEPR* rs6588147 G\>A polymorphism and the risk of cancer, especially in Asians. In future, the association of this SNP with cancer susceptibility should be further studied with a large sample size. Also, functional studies are needed to identify the real biologic function of *LEPR* rs6588147 G\>A polymorphism on the development of HCC.

There are some limitations in this study. First, since the number of HCC cases and controls was moderate, the power of study might be limited. Second, the HCC cases and controls were both enrolled from local hospitals. Therefore, selection bias should have occurred. Third, for lack of some important data, such as lifestyle, dietary habits, and environmental carcinogens exposure, the interaction of gene--environment was not studied. Fourth, the information available on HCC survival has been insufficient till now; thus, we could not further analyze the potential role of *LEP*/*LEPR* functional polymorphisms in HCC progression and prognosis. Fifth, due to lack of sufficient information on height and weight, the body mass index was not considered in this study. Finally, we only selected some functional SNPs in *LEP* and *LEPR* genes, and a fine-mapping or Genome Wide Association study focusing on *LEP* and *LEPR* genes should be performed to further explore the potential relationship of *LEP* and *LEPR* SNPs with the risk of HCC.

To sum up, this study has demonstrated that *LEP* rs7799039 A\>G and rs2167270 G\>A polymorphisms are genetic risk factors for HCC with various degrees of relationship in an Eastern Chinese Han population. However, *LEPR* rs6588147 G\>A may decrease the risk of HCC. Further epidemiologic case--control studies are needed to assess the interaction of *LEP* and *LEPR* genotypes with the exposure to environmental carcinogens, lifestyle, and dietary habits.
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###### 

Distribution of selected demographic variables and risk factors in HCC cases and controls

  Variables               Cases (n=584)    Controls (n=923)   *P*-value[a](#tfn1-ott-11-2083){ref-type="table-fn"}           
  ----------------------- ---------------- ------------------ ------------------------------------------------------ ------- --
  Age (years)             53.17 (±11.76)   53.72 (±9.97)      0.327                                                          
  Age (years)             0.358                                                                                              
   \<53                   264              45.21              395                                                    42.80   
   ≥53                    320              54.79              528                                                    57.20   
  Sex                     0.717                                                                                              
   Male                   525              89.90              835                                                    90.47   
   Female                 59               10.10              88                                                     9.53    
  Smoking status          0.834                                                                                              
   Never                  374              64.04              596                                                    64.57   
   Ever                   210              35.96              327                                                    35.43   
  Alcohol use             \<0.001                                                                                            
   Never                  414              70.89              775                                                    83.97   
   Ever                   170              29.11              148                                                    16.03   
  Chronic HBV infection   \<0.001                                                                                            
   Yes                    412              70.55              85                                                     9.21    
   No                     172              29.45              838                                                    90.79   
  BCLC classification                                                                                                        
   A                      392              67.12                                                                             
   B                      175              29.97                                                                             
   C                      17               2.91                                                                              

**Note:**

Two-sided *χ*^2^-test and Student's *t*-test.

**Abbreviations:** BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.

###### 

Primary information for *LEP* rs2167270 G\>A, rs7799039 A\>G, *LEPR* rs6588147 G\>A, rs1137100 G\>A, and rs1137101 G\>A polymorphisms

  Genotyped SNPs          Chromosome   Chr Pos (NCBI Build 37)   Region     MAF for Chinese in database   MAF in our controls (n=923)   *P*-value for HWE test in our controls   Genotyping method   Genotyping value (%)
  ----------------------- ------------ ------------------------- ---------- ----------------------------- ----------------------------- ---------------------------------------- ------------------- ----------------------
  *LEP* rs7799039 A\>G    7            127878783                 Promoter   0.201                         0.256                         0.439                                    SNPscan             99.27
  *LEP* rs2167270 G\>A    7            127881349                 5′ UTR     0.175                         0.213                         0.245                                    SNPscan             99.27
  *LEPR* rs1137100 G\>A   1            66036441                  Exon 4     0.169                         0.155                         0.203                                    SNPscan             99.27
  *LEPR* rs1137101 G\>A   1            66058513                  Exon 6     0.111                         0.116                         0.453                                    SNPscan             99.20
  *LEPR* rs6588147 G\>A   1            65935494                  Intron 2   0.150                         0.149                         0.097                                    SNPscan             99.27

**Abbreviations:** HWE, Hardy--Weinberg equilibrium; MAF, minor allele frequency; UTR, untranslated region.

###### 

Logistic regression analyses of association between *LEP* rs2167270 G\>A, rs7799039 A\>G, *LEPR* rs6588147 G\>A, rs1137100 G\>A, and rs1137101 G\>A SNPs and the risk of HCC

  Genotype                Cases (n=584)   Controls (n=923)   Crude OR (95% CI)   *P*-value   Adjusted OR[a](#tfn4-ott-11-2083){ref-type="table-fn"} (95% CI)   *P*-value                           
  ----------------------- --------------- ------------------ ------------------- ----------- ----------------------------------------------------------------- ----------- ----------------------- -----------
  *LEP* rs7799039 A\>G                                                                                                                                                                             
   AA                     295             51.30              505                 54.83       1.00                                                                          1.00                    
   AG                     221             38.43              360                 39.09       1.02 (0.82--1.28)                                                 0.834       1.11 (0.83--1.48)       0.498
   GG                     59              10.26              56                  6.08        **1.76 (1.19--2.60)**                                             **0.005**   **2.03 (1.22--3.38)**   **0.006**
   AG+GG                  280             48.70              416                 45.17       1.15 (0.94--1.42)                                                 0.183       1.25 (0.95--1.65)       0.110
   AA+AG                  516             89.74              865                 93.92       1.00                                                                          1.00                    
   GG                     59              10.26              56                  6.08        **1.77 (1.21--2.59)**                                             **0.004**   **1.97 (1.20--3.22)**   **0.007**
   G allele               339             29.48              472                 25.62                                                                                                             
  *LEP* rs2167270 G\>A                                                                                                                                                                             
   GG                     343             59.65              564                 61.24       1.00                                                                          1.00                    
   GA                     198             34.43              321                 34.85       0.99 (0.80--1.24)                                                 0.942       1.04 (0.78--1.40)       0.774
   AA                     34              5.91               36                  3.91        1.52 (0.93--2.47)                                                 0.093       **2.03 (1.10--3.75)**   **0.024**
   GA+AA                  232             40.35              357                 38.76       1.07 (0.86--1.32)                                                 0.541       1.15 (0.87--1.53)       0.316
   GG+GA                  541             94.09              885                 96.09       1.00                                                                          1.00                    
   AA                     34              5.91               36                  3.91        1.55 (0.96--2.50)                                                 0.076       **2.01 (1.10--3.68)**   **0.023**
   A allele               266             23.13              393                 21.34                                                                                                             
  *LEPR* rs6588147 G\>A                                                                                                                                                                            
   GG                     444             77.22              661                 71.77       1.00                                                                          1.00                    
   GA                     123             21.39              246                 26.71       **0.73 (0.57--0.94)**                                             **0.013**   **0.62 (0.45--0.86)**   **0.005**
   AA                     8               1.39               14                  1.52        0.84 (0.35--2.01)                                                 0.690       0.85 (0.27--2.69)       0.777
   GA+AA                  131             22.78              260                 28.23       **0.75 (0.59--0.96)**                                             **0.020**   **0.64 (0.47--0.88)**   **0.007**
   GG+GA                  567             98.61              907                 98.48       1.00                                                                          1.00                    
   AA                     8               1.39               14                  1.52        0.92 (0.38--2.20)                                                 0.842       0.96 (0.31--3.03)       0.947
   A allele               139             12.09              274                 14.88                                                                                                             
  *LEPR* rs1137100 G\>A                                                                                                                                                                            
   GG                     424             73.74              653                 70.90       1.00                                                                          1.00                    
   GA                     143             24.87              251                 27.25       0.86 (0.68--1.09)                                                 0.222       0.75 (0.55--1.03)       0.074
   AA                     8               1.39               17                  1.85        0.71 (0.31--1.66)                                                 0.433       0.62 (0.20--1.92)       0.408
   GA+AA                  151             26.26              268                 29.10       0.87 (0.69--1.10)                                                 0.235       0.75 (0.55--1.02)       0.069
   GG+GA                  567             98.61              904                 98.15       1.00                                                                          1.00                    
   AA                     8               1.39               17                  1.85        0.75 (0.32--1.75)                                                 0.506       0.68 (0.22--2.07)       0.496
   A allele               159             27.65              285                 15.47                                                                                                             
  *LEPR* rs1137101 G\>A                                                                                                                                                                            
   GG                     453             78.78              717                 77.93       1.00                                                                          1.00                    
   GA                     119             20.70              193                 20.98       0.96 (0.74--1.24)                                                 0.761       0.81 (0.58--1.14)       0.230
   AA                     3               0.52               10                  1.09        0.47 (0.13--1.71)                                                 0.251       0.22 (0.05--1.10)       0.065
   GA+AA                  122             21.22              203                 22.07       0.95 (0.74--1.23)                                                 0.700       0.78 (0.56--1.09)       0.152
   GG+GA                  572             99.48              910                 98.91       1.00                                                                          1.00                    
   AA                     3               0.52               10                  1.09        0.48 (0.13--1.74)                                                 0.264       0.24 (0.05--1.16)       0.076
   A allele               125             10.87              213                 11.58                                                                                                             

**Notes:**

Adjusted for age, sex, smoking status, alcohol use, and chronic HBV infection status. Bold values are statistically significant (*P*\<0.05).

**Abbreviations:** HBV, hepatitis B virus; HCC, hepatocellular carcinoma; LEP, leptin; LEPR, LEP receptor; OR, odds ratio; SNPs, single-nucleotide polymorphisms.
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